Clinical Trials Browser

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT03016871 2025-10-20

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Phase 2 Active not recruiting

78 enrolled 15 charts

Lymphoid

Hodgkin Disease

NCT04050462 2025-10-16

Nivolumab Combined With BMS-986253 in HCC Patients

Phase 2 Terminated

13 enrolled 13 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03573947 2025-10-14

TOP1705

Phase 2 Completed

46 enrolled 14 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03404960 2025-10-10

Parpvax

Phase 1/2 Completed

104 enrolled 11 charts

Gastrointestinal

Pancreatic Adenocarcinoma

NCT03963518 2025-10-06

SURROGATE-ICI

Completed

631 enrolled 6 charts

Tumor-Agnostic

Neoplasms

NCT03414684 2025-09-29

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Phase 2 Active not recruiting

78 enrolled 46 charts

Breast

Breast Neoplasms

NCT03711058 2025-09-16

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Phase 1/2 Completed

48 enrolled 16 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Spinocerebellar Degenerations

NCT04057365 2025-08-13

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)

Phase 2 Terminated

15 enrolled 8 charts

Gastrointestinal

Biliary Tract Neoplasms

Clinical Trials

Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma

Nivolumab With or Without Ipilimumab or Chemotherapy in Treating Patients With Previously Untreated Stage I-IIIA Non-small Cell Lung Cancer

CPIT001

Cetuximab & Nivolumab in Patients With Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma

Phase I/II Study of Nivolumab and Ipilimumab Combined With Nintedanib in Non Small Cell Lung Cancer

A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

IMAGINE

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies

Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma

Study of Nivolumab in Patients With Advanced Refractory Biliary Tract Cancers

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma

Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma

DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia

Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable Non-Small Cell Lung Cancer

Neoadjuvant Immunotherapy With Tavo + Electroporation in Combination With Nivo. in Melanoma Patients

ALT-803 Plus Nivolumab in Patients With Pretreated, Advanced or Metastatic Non-Small Cell Lung Cancer

METIMMOX

Phase Ib/II Trial of Nal-Irinotecan and Nivolumab as Second-Line Treatment in Patients With Advanced Biliary Tract Cancer

Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma

Study of Optimized Management of Nivolumab Based on Response in Patients With Advanced RCC (OMNIVORE Study)

NIMBUS: Nivolumab Plus Ipilimumab in Metastatic Hypermutated HER2-negative Breast Cancer

Ipilimumab With or Without Nivolumab in Relapsed/Refractory cHL

Window Study of Nivolumab With or Without Ipilimumab in Squamous Cell Carcinoma of the Oral Cavity

An Open-Label Phase II Study of Nivolumab or Nivolumab/Ipilimumab in Adult Participants With Progessive/ Recurrent Meningioma

Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer

Nivolumab + Chemoradiation in Stage II-IVB Nasopharyngeal Carcinoma (NPC)

Biomarkers of Response to Ipilimumab and Nivolumab in First-line NSCLC

Personalized Immunotherapy in Patients With Recurrent /Metastatic SCCHN That Have Progressed on Prior Immunotherapy

Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma

Study of Nivolumab Plus Ipilimumab in Patients With Salivary Gland Cancer

Nivolumab for the Reversal of Squamous Dysplasia in High Risk Current and Former Smokers

NA_00092076

BMS-986156, Ipilimumab, and Nivolumab With or Without Stereotactic Body Radiation Therapy in Treating Patients With Advanced or Metastatic Lung/Chest or Liver Cancers

Ipilimumab and Nivolumab in Leptomeningeal Metastases

Trial of Nivolumab as a Novel Neoadjuvant Pre-Surgical Therapy for Locally Advanced Oral Cavity Cancer

TG4010 and Nivolumab in Patients With Lung Cancer

Nivolumab for Recurrent or Progressive IDH Mutant Gliomas

Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies

Nivolumab, Ifosfamide, Carboplatin, and Etoposide as Second-Line Therapy in Treating Patients With Refractory or Relapsed HL

Nivolumab Combined With BMS-986253 in HCC Patients

TOP1705

Parpvax

SURROGATE-ICI

Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer

Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer

Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC)